Business Context and Reporting Period
This Form 8-K is a current report filed by MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) on July 2, 2021, covering the date of the earliest event reported on June 30, 2021. The filing addresses corporate governance and executive compensation matters under Item 5.02.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the expiration of the CFO Consulting Agreement between the Company and Brio Financial Group on June 30, 2021. Despite the expiration, Ian Rhodes will continue to serve as the interim Chief Financial Officer under the same terms as the previous agreement.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. The document is limited to confirming the continuation of the interim CFO arrangement.
Investor Verification Checklist
- Verify the specific terms of the renewed interim CFO arrangement to ensure they match the expired agreement.
- Confirm the duration of the new interim arrangement, as the filing does not specify an end date.
- Review subsequent filings for any updates on the appointment of a permanent Chief Financial Officer.